Summary
Cannot verify adherence to FDA-approved prescribing information because the available label sections provided contain placeholders/empty content for key safety-relevant sections, and the extracted claims are not supported by the provided label text.
Category Scores
Accurate Statements
Unsupported Statements
Lipitor (atorvastatin) launched in 1996.
Not supported by the provided label sections.
Lipitor peaked at $125 billion in U.S. sales.
Not supported by the provided label sections.
Lipitor's 2011 patent expiration triggered generic entry.
Not supported by the provided label sections.
Generic entry slashed prices from more than $4 per pill to under 10 cents.
Not supported by the provided label sections.
Generic atorvastatin now costs $0.05–$0.20 per dose via chains like Walmart and GoodRx.
Not supported by the provided label sections.
Within months of generic launch, prices fell 80–90%.
Not supported by the provided label sections.
Generic competition resolved most issues rapidly.
Not supported by the provided label sections.
U.S. spending on atorvastatin dropped from $3.5 billion in 2010 to under $200 million by 2013.
Not supported by the provided label sections.
Patient out-of-pocket costs averaged $10–20/month pre-generic.
Not supported by the provided label sections.
Patient out-of-pocket costs are $5 or less today.
Not supported by the provided label sections.
No major recent interventions target Lipitor generics specifically.
Not supported by the provided label sections.
Pfizer's 2011 authorized generic (via Watson) accelerated access without litigation delays.
Not supported by the provided label sections.
Pfizer's co-pay cards and patient assistance programs cap costs at $4–$25/month for eligible uninsured/low-income users.
Not supported by the provided label sections.
Pfizer's co-pay cards and patient assistance programs are available via pfizer.com.
Not supported by the provided label sections.
Medicare Part D covers generics at low copays, often $0–$5.
Not supported by the provided label sections.
The Inflation Reduction Act (2022) caps insulin but not statins directly.
Not supported by the provided label sections.
The Inflation Reduction Act enhances negotiation for high-cost drugs.
Not supported by the provided label sections.
Programs like GoodRx, SingleCare, and Amazon Pharmacy offer atorvastatin at $3–$8 for 30 days.
Not supported by the provided label sections.
The atorvastatin price from these programs is 90% below brand cash price.
Not supported by the provided label sections.
Walmart's $4 generic list includes atorvastatin.
Not supported by the provided label sections.
Eighty percent of prescriptions are now generic.
Not supported by the provided label sections.
WHO's prequalification and compulsory licensing enabled low-cost generics earlier in developing countries.
Not supported by the provided label sections.
Cipla's atorvastatin version has cost $0.02/pill since 2003.
Not supported by the provided label sections.
Médecins Sans Frontières pushes pooled procurement for statins in low-income regions.
Not supported by the provided label sections.
Switching statins requires doctor input.
Not explicitly supported by the provided label text.
All listed statins are interchangeable for most.
Not supported by the provided label sections.
Contradictions
Important Omissions
Key prescribing elements (e.g., detailed Dosage and Administration content, Contraindications content, Warnings and Precautions content, Adverse Reactions details, Use in Specific Populations details) are not provided (placeholders such as 'Enter section text here' or empty/links without text), so safety-relevant verification is not possible.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Because the provided label content does not include the necessary safety-relevant sections, the extracted claims cannot be evaluated for label-concordant contraindications, warnings, dosing, monitoring, or specific-population safety. Additionally, the extracted claims focus on market/policy/pricing statements rather than label-supported prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
No extracted claims are supported by the provided FDA label text; key label sections needed for safety verification are missing/placeholder.
Suggested Improvement
Limit statements to information explicitly present in the provided label text (e.g., indications/diet adjunct concept and the specific listed interaction risk categories if dosage/administration and safety sections are supplied). Provide complete label sections for contraindications, warnings/precautions, dosage/administration, and specific-population content before making safety- or therapy-relevant claims.